Bernard A. Fox: Cancer Immunotherapy Pioneer John Haanen Receives ITOC12 Lifetime Achievement Award
Bernard A. Fox and John Haanen

Bernard A. Fox: Cancer Immunotherapy Pioneer John Haanen Receives ITOC12 Lifetime Achievement Award

Bernard A. Fox, Co – founder, President, and CEO of UbiVac, shared a post on LinkedIn:

“Prof. John Haanen, cancer immunotherapy RockSTAR at The Netherlands Cancer Institute receives the ITOC12, Lifetime Achievement Award!

Well deserved recognition for more than three decades of tumor immunology research and efforts that have improved outcomes for patients with cancer!

Keep up the good work my friend!”

Proceed to watch the video attached to the post.

Other articles featuring Bernard A. Fox on OncoDaily.